HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling.

Abstract
Recurrence and chemoresistance of liver cancer has been attributed to the existence of liver tumor-initiating cells (T-ICs). It is important to decipher the molecular mechanism for acquisition of drug resistance and to design combinatorial therapeutic strategies. Cyclin G1 has been shown to play a pivotal role in initiation and metastasis of hepatocellular carcinoma. In this study, we found that enhanced cyclin G1 expression was associated with drug resistance of hepatoma cells and higher recurrence rate in hepatocellular carcinoma patients. Expression of cyclin G1 was elevated in liver T-ICs and closely correlated with the expression of liver T-IC markers. Forced cyclin G1 expression remarkably enhanced self-renewal and tumorigenicity of hepatoma cells. Cyclin G1 overexpression dramatically upregulated the expression of Sox2 both in vitro and in vivo, which was impaired by chemical inhibitors of Akt/mTOR signaling. Furthermore, blockade of Akt/mTOR signaling or interference of Sox2 expression suppressed cyclin G1-enhanced self-renewal, chemoresistance, and tumorigenicity of hepatoma cells, indicating that cyclin G1 expands liver T-ICs through Sox2 induction via Akt/mTOR signaling pathway. These results suggest that cyclin G1-induced liver T-IC expansion contributes to the recurrence and chemoresistance of hepatoma, and cyclin G1 may be a promising biomarker for individualized therapy of hepatocellular carcinoma patients.
AuthorsWen Wen, Tao Han, Cheng Chen, Lei Huang, Wen Sun, Xue Wang, Shu-Zhen Chen, Dai-Min Xiang, Liang Tang, Dan Cao, Gen-Sheng Feng, Meng-Chao Wu, Jin Ding, Hong-Yang Wang
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 12 Issue 9 Pg. 1796-804 (Sep 2013) ISSN: 1538-8514 [Electronic] United States
PMID23804702 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CCNG1 protein, human
  • Ccng1 protein, mouse
  • Cyclin G1
  • Phenylurea Compounds
  • SOX2 protein, human
  • SOXB1 Transcription Factors
  • Sox2 protein, mouse
  • Niacinamide
  • Sorafenib
  • MTOR protein, human
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • Cisplatin
Topics
  • Animals
  • Apoptosis (drug effects, genetics)
  • Carcinoma, Hepatocellular (drug therapy, genetics, metabolism, pathology)
  • Cell Line, Tumor
  • Cisplatin (therapeutic use)
  • Cyclin G1 (genetics, metabolism)
  • Drug Resistance, Neoplasm
  • Gene Expression Regulation, Neoplastic
  • Heterografts
  • Humans
  • Liver Neoplasms (drug therapy, genetics, metabolism, pathology)
  • Male
  • Mice
  • Mice, SCID
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Neoplasm Transplantation
  • Neoplastic Stem Cells (drug effects, pathology, physiology)
  • Niacinamide (analogs & derivatives, therapeutic use)
  • Phenylurea Compounds (therapeutic use)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • SOXB1 Transcription Factors (genetics, metabolism)
  • Signal Transduction (drug effects, genetics)
  • Sorafenib
  • TOR Serine-Threonine Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: